Legacy continuation of the KU CMLD Mission
KU CMLD 使命的延续
基本信息
- 批准号:8753214
- 负责人:
- 金额:$ 54.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-08-01 至 2017-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAwardBackBiologicalBiological AssayBiologyBiomedical ResearchChargeChemicalsClientClinical TrialsCollectionCommunitiesDevelopmentElementsEnsureEvaluationFundingFunding MechanismsFunding OpportunitiesFutureGoalsKansasLibrariesLibrary Collection DevelopmentLiquid ChromatographyMaintenanceMethodologyMethodsMetricMissionModelingMolecular BankNIH Program AnnouncementsNational Institute of General Medical SciencesPharmaceutical ChemistryPowder dose formPreparationProcessPublic SectorPublicationsPublishingQuality ControlRecoveryResearchResearch PersonnelResearch Project GrantsResourcesSamplingScientistStagingStructureTestingUnited States National Institutes of HealthUniversitiesValidationanalogbasecostdrug discoveryhigh throughput screeninginterestmembermilligramnoveloperationoutreachprogramspublic health relevancerepositoryscreeningsmall moleculesmall molecule libraries
项目摘要
DESCRIPTION (provided by applicant): To provide academic researchers with high-quality compound collections for biological screening, the National Institute of General Medical Sciences established the Chemical Methodologies and Library Development (CMLD) Network and charged it with developing new ways of creating libraries and providing them to the SMR. The CMLD network was maintained under a R41 funding mechanism and has been discontinued, making it eligible for consideration as a legacy resource under the present program announcement. As part of the CMLD network, the University of Kansas CMLD center was responsible for developing numerous chemical methods and for providing >7000 compounds to the SMR. Most excitingly, numerous KU CMLD center compounds have been identified as hits in diverse screens, with a few progressing to full-blown development efforts currently underway. The NIH plans to maintain the SMR for the foreseeable future, with new screens being enabled by currently active, project-specific R01 awards (PAR-12-058), meaning that new hits will continue to be identified. However, the ability of researchers to have continued
access to non-commercial compounds, which constitute a valuable and unique asset of the repository, is threatened by diminishing supplies of these compounds, many of which have been depleted. This threat is particularly acute with respect to pure samples (generally powders) that are essential for validation efforts following the initial screen. We propose to address these concerns through the present program. Our near-term goal is to supply scientists who have uncovered screening hits in the SMR with structurally validated quantitatively quality-controlled samples of the hit of interest as well as chemically similar analogs for validation efforts. This wll require a sustained effort in scientific outreach to maximize the potential client base for these activities as well as technical maintenance of our synthetic and compound purification/management capabilities Our long-term goal is to transform our library synthesis and hit validation activities into a sustainable effort that will eventually be supported by cost recovry from project-specific research grants and charge-backs to clients.
描述(由申请人提供):为了向学术研究人员提供用于生物筛选的高质量化合物收藏,国家普通医学科学研究所建立了化学方法学和图书馆开发(CMLD)网络,并负责开发创建图书馆的新方法并将其提供给SMR。CMLD网络是在R41供资机制下维持的,并已停止使用,使其有资格作为本方案公告所述的遗留资源予以考虑。作为CMLD网络的一部分,堪萨斯大学CMLD中心负责开发多种化学方法,并向SMR提供7000种化合物。最令人兴奋的是,许多KU CMLD中心化合物已经在不同的屏幕上被确定为热门,其中一些正在进行全面的开发工作。NIH计划在可预见的未来保持SMR,目前活跃的、特定于项目的R01奖项(PAR-12-058)将启用新的屏幕,这意味着将继续识别新的热门歌曲。然而,研究人员的能力继续
非商业性化合物是储存库的一项宝贵而独特的资产,但由于这些化合物的供应不断减少,其中许多已经耗尽,对这些化合物的获取构成了威胁。这一威胁对于初始筛查后的验证工作至关重要的纯样品(通常是粉末)尤其严重。我们建议通过目前的方案来解决这些关切。我们的近期目标是为在SMR中发现筛选命中的科学家提供感兴趣的命中的结构验证、定量质量控制的样本,以及用于验证工作的化学上类似的类似物。这将需要在科学推广方面的持续努力,以最大限度地扩大这些活动的潜在客户基础,以及对我们的合成和化合物纯化/管理能力进行技术维护。我们的长期目标是将我们的图书馆合成和验证活动转变为一项可持续的努力,最终将得到来自特定项目研究赠款和客户退款的成本回收的支持。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THOMAS EDWARD PRISINZANO其他文献
THOMAS EDWARD PRISINZANO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THOMAS EDWARD PRISINZANO', 18)}}的其他基金
Development of Agents for Synthetic Opioid Overdose
合成阿片类药物过量药物的开发
- 批准号:
10275603 - 财政年份:2021
- 资助金额:
$ 54.06万 - 项目类别:
Development of Agents for Synthetic Opioid Overdose
合成阿片类药物过量药物的开发
- 批准号:
10672919 - 财政年份:2021
- 资助金额:
$ 54.06万 - 项目类别:
Development of Agents for Synthetic Opioid Overdose
合成阿片类药物过量药物的开发
- 批准号:
10470923 - 财政年份:2021
- 资助金额:
$ 54.06万 - 项目类别:
Investigation of Neoclerodanes as Novel Opioid Ligands
新克莱丹作为新型阿片类配体的研究
- 批准号:
9030515 - 财政年份:2016
- 资助金额:
$ 54.06万 - 项目类别:
Investigation of Neoclerodanes as Novel Opioid Ligands
新克莱丹作为新型阿片类配体的研究
- 批准号:
9266380 - 财政年份:2016
- 资助金额:
$ 54.06万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 54.06万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 54.06万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 54.06万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 54.06万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 54.06万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 54.06万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 54.06万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 54.06万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 54.06万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 54.06万 - 项目类别:
Research Grant














{{item.name}}会员




